Guess which ASX 300 share has rocketed 27% in 2 days since reporting

A barrage of news has sent one stock soaring this week.

| More on:
Health workers shake hands and congratulate each other on good news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Mayne Pharma share price is trading at $4 right now – 27% higher than it was prior to entering a trading halt ahead of Monday's open
  • The company announced a US$90 million divestment and the cancellation of its capital return over the course of Monday and Tuesday
  • It also released its earnings for the first half yesterday morning, with management dubbing the performance of some of its businesses "disappointing"

The share price of S&P/ASX 300 Index (ASX: XKO) stock Mayne Pharma Group Ltd (ASX: MYX) has soared since the company dropped its half-year earnings on Tuesday morning.

Right now, the pharmaceutical manufacturer's stock is trading at $4 – 27% higher than it was before it broke a trading halt with news of its results, a divestment, and its capital return.

Let's take a closer look at what's been going right for the ASX 300 share this week.

ASX 300 share Mayne Pharma rockets 27% in 2 sessions

Here are the key takeaways from Mayne Pharma's first-half earnings:

The company's earnings were dinted by lower revenues, driven by higher inventory levels, discontinued products, and foreign exchange losses.

The company's branded products division saw revenue more than triple to $13.4 million last half amid strong growth in NEXSTELIS sales. Its portfolio products division saw revenue fall 49% to $60.1 million. Finally, its international segment's revenue was flat at $27.6 million.

What else did the company announce this week?

The Mayne Pharma share price was put into a trading halt on Monday morning, returning to trade on Tuesday, as the ASX 300 company prepared to release news of a material divestment and its capital management.

Later that day, it announced the sale of its US retail generics portfolio business for up to US$90 million cash and up to US$15 million of contingent milestone payments.

The move supports the company's aim to transform into a speciality pharmaceutical company with leading positions in women's health and dermatology.

It also announced the cancellation of its $113 million capital return on Tuesday. It said the return was no longer in the company's best interests.

What did management say?

Mayne Pharma CEO Shawn Patrick O'Brien commented on the news seemingly driving the ASX 300 share sky-high in recent sessions, saying:

We have taken decisive action this half to address the issues that have created the disappointing results in both our PPD and International businesses.

We are creating a leaner company with strong commercial and sales execution capabilities and [with the sale of the US retail generics business] we move a step closer to achieving our goal of generating operating cash and returning the business to profitability.

The board is supportive of our strategy and ambition, and the cancellation of the capital return is a prudent step to retain balance sheet flexibility whilst we drive improved operating performance, and the board considers the appropriate capital structure to support profitable growth and a restoration of shareholder value.

What's next?

The company heralded an encouraging start to the second half. It flagged improvement in its dermatology segment and positive impacts from the scaling up of its US women's health business.

The latter is on track to exit financial year 2023 with a positive run rate contribution. Meanwhile, the newly acquired TherapeuticsMD portfolio is expected to deliver positive earnings in the second half.

At the same time, launches of various products are expected to drive growth across the company.

Maybe Pharma share price underperforms the ASX 300

Despite this week's surge, the Mayne Pharma share price is still in the longer-term red.

It has fallen 5% so far this year and 13% over the last 12 months.

For comparison, the ASX 300 has gained 4% year to date and 2% over the last 12 months.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

Photo of two women shopping.
Earnings Results

Premier Investments share price jumps 9% on results and demerger plans

The Smiggle and Peter Alexander owner has released its results. How did it perform?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Earnings Results

Soul Patts share price struggles on falling profits

ASX 200 investment house Soul Patts reported its half year results this morning.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Earnings Results

Brickworks share price tumbles on disappointing half-year loss

This loss didn't stop the company from increasing its dividend again.

Read more »

A man sits on a bench atop a mountain with a laptop, making investments with a green ESG mind.
Earnings Results

ASX All Ords stock KMD tumbles as interim dividend cancelled

Investors are hitting the sell button on ASX All Ords stock KMD today.

Read more »

Coal miner holding a giant coal rock in his hand making a circle with his hand, symbolising a rising share price.
Energy Shares

New Hope share price charges higher despite profit crunch and huge dividend cut

Weaker coal prices have hit this miner's profits and dividend hard.

Read more »

A Chinese investor sits in front of his laptop looking pensive and concerned about pandemic lockdowns which may impact ASX 200 iron ore share prices
Earnings Results

Liontown share price tumbles 7% on half-year results

This lithium developer's results have been released this afternoon.

Read more »

A man in a hard hat and high visibility vest holds his thumb up in a gesture of confidence with heavy moving equipment in the background as on a mine site as the Chalice Mining share price rises today.
Earnings Results

Sayona Mining share price jumps despite $32m half-year loss

The Sayona Mining Ltd (ASX: SYA) share price is pushing higher on Thursday. At the time of writing, the lithium…

Read more »